Balance of R&D Tax Incentive Refund received
Filed with ASX · · 2 pages · English
Story so far
Earlier from AdAlta
- 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer
- R&D Tax Incentive Refund received
- Quarterly Appendix 4C and Activities Report
- AD-214 program update, cash runway extension
- European Patent for AD-214 granted
Later from AdAlta
- AD-214 progress and priorities
- AD-214 progress and priorities webinar presentation
- Second Japan patent for AD-214
- AdAlta welcomes new substantial shareholders
- Publication highlights I-body potential in osteoporosis
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta